Differential Effects of Megavitamin E on Prostacyclin and Thromboxane Synthesis in Streptozotocin-Induced Diabetic Rats

Diabetic subjects tend to develop microvascular complications believed to be due to platelet hyperaggregability. This increased platelet sensitivity is though to be the result of an imbalance of PGI2 and TXA2 production in diabetes. This study sought to determine whether megavitamin E supplementation could restore PGI2/TXA2 balance in streptozotocin-diabetic rats. Endogenous release of PGI2 by isolated aorta, determined via radioimmunoassay of its stable metabolite, 6-keto-PGF1 alpha, was significantly greater (P less than 0.05) in rats receiving 100x the normal vitamin E requirement than in untreated diabetic rats. PGI2 synthesis was negatively correlated with plasma glucose levels (r = -0.87, P less than 0.05) in non-fasted rats at sacrifice. Vitamin E supplementation, at both the 10x and the 100x level, significantly depressed (P less than 0.05) thrombin-stimulated synthesis of TXA2 in washed platelet. PGI2 and TXA2 production were expressed as a ratio. Megavitamin E therapy appears to increase this ratio over that seen in the diabetic animal. The data suggest that vitamin E, at high levels, exerts an ameliorating influence of the PGI2/TXA2 imbalance of diabetes.

[1]  W. Förster.  In vivo and ex vivo studies of the effect of vitamin E pre-treatment on PGI2 and TXA2 synthesis. , 2009, Acta medica Scandinavica. Supplementum.

[2]  A. Butkus,et al.  Thromboxane production and platelet aggregation in diabetic subjects with clinical complications. , 1980, Thrombosis research.

[3]  J. White,et al.  Alteration in the balance of prostaglandin and thromboxane synthesis in diabetic rats. , 1980, The Journal of laboratory and clinical medicine.

[4]  J. McDonald,et al.  Inhibition of human platelet cyclooxygenase by alpha-tocopherol. , 1980, Prostaglandins and medicine.

[5]  J. M. Bailey,et al.  Prostacyclins, thromboxanes and cardiovascular disease , 1979 .

[6]  H. Sinzinger,et al.  Coexistence of deficiency in alpha1 antitrypsin and in growth hormone. , 1979 .

[7]  J. Elder,et al.  VASCULAR PROSTACYCLIN MAY BE REDUCED IN DIABETES IN MAN , 1979, The Lancet.

[8]  E. Zebrowski,et al.  Urinary excretion pattern of ascorbic acid in streptozotocin diabetic and insulin treated rats. , 1979, Pharmacological research communications.

[9]  H. Harrison,et al.  Decreased vascular prostacyclin in experimental diabetes. , 1978, Life sciences.

[10]  D. Cornwell,et al.  Differential inhibitory effects of vitamin E and other antioxidants on prostaglandin synthetase, platelet aggregation and lipoxidase. , 1977, Prostaglandins.

[11]  M. Laimins,et al.  Correlation of platelet aggregation, plasma factor activity, and megathrombocytes in diabetic subjects with an without vascular disease. , 1977, Metabolism: clinical and experimental.

[12]  R. Egan,et al.  Mechanism for irreversible self-deactivation of prostaglandin synthetase. , 1976, The Journal of biological chemistry.

[13]  M. Steiner,et al.  Vitamin E. An inhibitor of the platelet release reaction. , 1976, The Journal of clinical investigation.

[14]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[15]  M. Carpenter.  Antioxidant effects on the prostaglandin endoperoxide synthetase product profile. , 1981, Federation proceedings.

[16]  W. Lands.  The biosynthesis and metabolism of prostaglandins. , 1979, Annual review of physiology.

[17]  H. Robinson.  Principles and Procedures of Statistics , 1961 .